Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

The purpose of this study is to obtain information on the effects of two doses of CHF6001 on sputum and blood biomarkers of inflammation in subjects with symptomatic COPD with moderate, severe airflow limitation and with chronic bronchitis. The efficacy of the treatment will also be measured using forced oscillometry technique and spirometry. Safety, tolerability and pharmacokinetics will be evaluated.